"Hemarthrosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Bleeding into the joints. It may arise from trauma or spontaneously in patients with hemophilia.
Descriptor ID |
D006395
|
MeSH Number(s) |
C05.550.459 C23.550.414.794
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hemarthrosis".
Below are MeSH descriptors whose meaning is more specific than "Hemarthrosis".
This graph shows the total number of publications written about "Hemarthrosis" by people in this website by year, and whether "Hemarthrosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2012 | 1 | 0 | 1 |
2015 | 1 | 0 | 1 |
2017 | 1 | 1 | 2 |
2019 | 0 | 1 | 1 |
2020 | 1 | 0 | 1 |
2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hemarthrosis" by people in Profiles.
-
Long-term safety and efficacy of the anti-tissue factor pathway inhibitor marstacimab in participants with severe haemophilia: Phase II study results. Br J Haematol. 2023 01; 200(2):240-248.
-
BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for =2 years. Eur J Haematol. 2020 Jun; 104(6):594-601.
-
Bleeding and safety outcomes in persons with haemophilia A without inhibitors: Results from a prospective non-interventional study in a real-world setting. Haemophilia. 2019 Mar; 25(2):213-220.
-
The potential correlation between patient-reported symptoms and the use of additional haemostatic medication for joint bleeding in haemophilia patients with inhibitors: a post hoc exploratory analysis of recombinant activated factor VII data from the ADEPT2 trial. Blood Coagul Fibrinolysis. 2017 Apr; 28(3):224-229.
-
Recombinant factor IX Fc fusion protein in children with haemophilia B (Kids B-LONG): results from a multicentre, non-randomised phase 3 study. Lancet Haematol. 2017 Feb; 4(2):e75-e82.
-
Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015 Jun; 13(6):967-77.
-
Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan; 10(1):81-9.